| Trial ID: | L6923 |
| Source ID: | NCT00517283
|
| Associated Drug: |
Exenatide And Placebo
|
| Title: |
A Study by Scintigraphy to Evaluate the Effect of Exenatide on Gastric Emptying in Subjects With Type 2 Diabetes
|
| Acronym: |
|
| Status: |
COMPLETED
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
Type 2 Diabetes Mellitus
|
| Interventions: |
DRUG: exenatide and placebo|DRUG: Exenatide and placebo|DRUG: Exenatide and placebo
|
| Outcome Measures: |
Primary: To detect the mean difference in half gastric emptying time for a solid meal between any treatment and placebo, A dose of exenatide or placebo is given before the morning meal. After eating the test meal, images will be recorded at approximately 5 minute intervals from ingestion of the test meal until 3 hours after the meal, then every 10 minutes until 6 hours after the meal. In cases where significant radioactivity is observed at 6 hours after the meal, additional scintigraphic images may be taken periodically at the discretion of the investigator, until counts approach low values for up to 12 hours after the meal., up to 12 hours post meal consumption |
|
| Sponsor/Collaborators: |
Sponsor: AstraZeneca | Collaborators: Eli Lilly and Company
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
PHASE1
|
| Enrollment: |
17
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: SINGLE (PARTICIPANT)|Primary Purpose: TREATMENT
|
| Start Date: |
2005-01
|
| Completion Date: |
2005-06
|
| Results First Posted: |
|
| Last Update Posted: |
2015-02-23
|
| Locations: |
Research Site, Nottingham, United Kingdom
|
| URL: |
https://clinicaltrials.gov/show/NCT00517283
|
